Antiretroviral pharmacokinetics in the paediatric population: a review.
about
Safety and effectiveness of combination antiretroviral therapy during the first year of treatment in HIV-1 infected Rwandan children: a prospective studyUnderdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study.Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children.The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets.Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience.Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy.Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children.Therapeutic drug monitoring in highly active antiretroviral therapy.Pharmacokinetics of anti-tuberculosis drugs in children.Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges.The challenges of pharmacokinetic variability of first-line anti-TB drugs.Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months.Effect of HIV genotypic drug resistance testing on the management and clinical course of HIV-infected children and adolescents.Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome.Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children.
P2860
Q34445856-F836005C-B3ED-4A38-A69C-E5E936C927EDQ34622948-02705373-FCA9-41D6-98C7-F44EBEEE9302Q35488671-87A2B7FE-360B-4E3D-8ED9-028C82C1E07DQ35917148-96FB8971-81D3-4012-860E-967022304313Q36276839-20831F0B-94C2-4EF6-ACF3-9C07F8E58976Q36376533-A5F153C5-A12C-43DD-8EE5-19F9802B9323Q37544540-DF8EF1C0-FBFE-4477-89B5-D4E4D362BB8CQ37720765-3BBDCB98-962B-400E-8A2C-234C348F4477Q37821811-401FA1C0-5055-4637-888A-8A2BAE4913DCQ37866289-A38293DA-D1A7-4F17-BA55-6043F2D25ED1Q38977166-8D59CD31-0BA9-4B1C-8BB9-B61AD4FC0A22Q41881433-FD79593B-402A-438E-A61A-6596C523A0B7Q42274720-231D8EEF-8815-49B0-B25E-3767B1A0EB69Q42661142-F02E98F9-BB9E-44AE-8F43-B64B5727A068Q45256524-7BA1F4F9-37F7-42F5-ADB8-913696E0AA6D
P2860
Antiretroviral pharmacokinetics in the paediatric population: a review.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Antiretroviral pharmacokinetics in the paediatric population: a review.
@ast
Antiretroviral pharmacokinetics in the paediatric population: a review.
@en
Antiretroviral pharmacokinetics in the paediatric population: a review.
@nl
type
label
Antiretroviral pharmacokinetics in the paediatric population: a review.
@ast
Antiretroviral pharmacokinetics in the paediatric population: a review.
@en
Antiretroviral pharmacokinetics in the paediatric population: a review.
@nl
prefLabel
Antiretroviral pharmacokinetics in the paediatric population: a review.
@ast
Antiretroviral pharmacokinetics in the paediatric population: a review.
@en
Antiretroviral pharmacokinetics in the paediatric population: a review.
@nl
P2093
P1476
Antiretroviral pharmacokinetics in the paediatric population: a review.
@en
P2093
David W Kimberlin
Edward P Acosta
Grace M Aldrovandi
Jennifer R King
P304
P356
10.2165/00003088-200241140-00001
P577
2002-01-01T00:00:00Z
P6179
1016856498